Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TNNC1 | P63316 | 5/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.31 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.31 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.31 |
| ▸ | GPR183 | P32249 | 1/20 | 0.31 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.30 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5065718 | 0.91 | EPHX1 (0.39) | EPHX1ALDH1A1TNNC1S1PR1S1PR4 | |
| SCHEMBL5012740 | 0.91 | EPHX1 (0.39) | EPHX1ALDH1A1TNNC1S1PR1S1PR4 | |
| SCHEMBL12968318 | 0.81 | EPHX1 (0.35) | EPHX1 | |
| SCHEMBL227493 | 0.80 | ALDH1A1 (0.42) | ALDH1A1TNNC1S1PR1S1PR4S1PR3 | |
| SCHEMBL165249 | 0.80 | ALDH1A1 (0.42) | ALDH1A1TNNC1S1PR1S1PR4S1PR3 | |
| SCHEMBL2346689 | 0.80 | ALDH1A1 (0.42) | ALDH1A1TNNC1S1PR1S1PR4S1PR3 | |
| Ammonia Solution, Strong SCHEMBL5707582 | 0.78 | ALDH1A1 (0.40) | ALDH1A1TNNC1S1PR1S1PR4S1PR3 | |
| SCHEMBL8910979 | 0.77 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL9352789 | 0.77 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL1050069 | 0.75 | ALDH1A1 (0.38) | ALDH1A1TNNC1S1PR1S1PR4S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1917268-A2 | PREPARATION OF 2,6-DIOXA-7-AZA-BICYCLO(2.2.2)OCTANES, AND THEIR USE IN COATINGS | E.I.Du pont de nemours and company (US) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007024835-A2 | PREPARATION OF 2,6-DIOXA-7-AZA-BICYCLO[2.2.2]OCTANES, AND THEIR USE IN COATINGS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049752-A1 | Preparation of 2,6-dioxa-7-aza-bicyclo[2.2.2] octanes | E. I. DU PONT DE NEMOURS AND COMPANY | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049752-A1 | Preparation of 2,6-dioxa-7-aza-bicyclo[2.2.2] octanes | OR10J3, DNMT1, TET3 | EPHX1 1065/4885ALDH1A1 672/4885TNNC1 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.